Evaluation and management of steroid-unresponsive nephrotic syndrome

Curr Opin Pediatr. 2008 Apr;20(2):151-6. doi: 10.1097/MOP.0b013e3282f4e6e4.

Abstract

Purpose of review: Idiopathic nephrotic syndrome in children is commonly associated with minimal change disease and response to steroid therapy. Steroid-unresponsive nephrotic syndrome is often characterized by persistent proteinuria and progression to chronic kidney disease. Focal segmental glomerulosclerosis is the leading cause of steroid-unresponsive nephrotic syndrome in childhood. There is no uniformed consensus as to the treatment of steroid-unresponsive nephrotic syndrome. Advances in the pathogenesis, genetics and biomarkers or surrogate markers may be useful for the diagnosis and identification of patients with steroid-unresponsive nephrotic syndrome, severity of disease, progression and response to therapy.

Recent findings: This review is intended to describe some of the recent changes in the epidemiology of steroid-unresponsive nephrotic syndrome, in particular focal segmental glomerulosclerosis, its pathogenesis and alternative therapies.

Summary: Recent studies in both children and adults have shown an increase in the incidence of focal segmental sclerosis as a cause of steroid-unresponsive nephrotic syndrome. Advances in the pathogenesis and noninvasive methods of diagnosis may allow for the identification of steroid-responsive patients.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Child
  • Cyclosporins / therapeutic use
  • Glomerulosclerosis, Focal Segmental / complications
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Mycophenolic Acid / analogs & derivatives
  • Mycophenolic Acid / therapeutic use
  • Nephrotic Syndrome / diagnosis*
  • Nephrotic Syndrome / drug therapy*
  • Nephrotic Syndrome / etiology
  • Randomized Controlled Trials as Topic
  • Sirolimus / therapeutic use
  • Tacrolimus / therapeutic use
  • Treatment Outcome

Substances

  • Cyclosporins
  • Immunosuppressive Agents
  • Mycophenolic Acid
  • Sirolimus
  • Tacrolimus